New User:

-or-
Username:
Password:
Forgot your password?
News Breaks
07:07 EDTALNY
theflyonthewall.com: Alnylam Pharmaceuticals issues update on RNAi pipeline
Alnylam Pharmaceuticals is providing an update on its RNAi pipeline, platform, and technology at its R&D Day being held in New York today. Alnylam scientists and management will be joined by two guest speakers: Professor Allan Glanville, Director of Thoracic Medicine and Medical Director Lung Transplantation, St. Vincent’s Hospital, Sydney, will discuss respiratory syncytial virus infection in the lung transplant patient population; and Professor Philip N. Hawkins, National Amyloidosis Centre, Division of Medicine, and University College London Medical School, Royal Free Hospital, will discuss transthyretin-mediated amyloidosis. Alnylam is developing RNAi therapeutics for the treatment of both RSV infection and ATTR, amongst other pipeline programs. :theflyonthewall.com



News For ALNY From The Last 14 Days
Check below for free stories on ALNY the last two weeks.
There is 1 item on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 8, 2010
08:13 EDTALNY
theflyonthewall.com: Alnylam awarded a Notice of Allowance for the Soutschek and Manoharan patent
Alnylam Pharmaceuticals announced that the United States Patent and Trademark Office has awarded a Notice of Allowance for the “Soutschek and Manoharan” patent, which covers certain chemically modified siRNAs of any length directed to any target, including siRNAs with sterol conjugates for in vivo delivery. The new patent is based on the ground-breaking research by Alnylam scientists on systemic delivery of RNAi therapeutics as documented in Soutschek et al. :theflyonthewall.com